Table 3.
Baseline medication selection of CAE patients after confirmed diagnosis
| Treatments | Group NC (n = 73) | CAE-A (n = 60) (age ≤ 50 years) | CAE-B (n = 83) (50 years<age ≤ 70 years) | CAE-C (n = 74) (age > 70 years) | Total CAE (A + B + C, n = 217) | p-value |
|---|---|---|---|---|---|---|
| ACEI/ARB | 18 | 16 | 27 | 28 | 71 | 0.895 |
| β-receptor blocker | 21 | 25 | 36 | 28 | 89 | 0.424 |
| Rosuvastatin | 73 | 60 | 83 | 74 | 217 | 0.945 |
| Calcium-channel blocker | 16 | 18 | 15 | 17 | 50 | 0.310 |
| Diuretics | 14 | 15 | 13 | 16 | 44 | 0.769 |
| Aspirin | 35 | 42 | 56 | 50 | 148 | 0.424 |
p-value: total CAE vs NC. CAE coronary artery ectasia, ACE angiotensin-converting enzyme